Impact of body mass index in Korean patients with renal cell carcinoma - Abstract

OBJECTIVE:The aim of the current study was to examine the impact of preoperative body mass index (BMI) in Korean patients with surgically treated renal cell carcinoma (RCC).

METHODS: From 1994 to 2008, a total of 1,487 patients underwent nephrectomy for RCC. All patients were classified into three groups according to Asian BMI classification by Asia Cohort Consortium: < 18.5, 18.5 to < 25, and 25 kg/m2or greater group, which represents the underweight (n = 42, 2.8%), normal (n = 833, 56.0%), and obesity (n = 612, 41.2%) group, respectively. Survival analyses and predictive factors for cancer-specific survival among the three groups were evaluated. Subgroup survival analysis of organ-confined and advanced disease was performed.

RESULTS:An overall median follow-up was 54.8 months. Mean ± SE estimated cancer-specific survival in all patients at 5 and 10 years was 88.0 ± 1.0% and 81.4 ± 1.4%, respectively. In the multivariate model after adjusting preoperative and postoperative variables, the underweight group had a significantly worse prognosis than the normal group (hazard ratio (HR): 2.17, 95% confidence interval (95% CI): 1.16-4.08, p = 0.016), meanwhile the obesity group was associated with improved survival (HR: 0.66, 95% CI: 0.45-0.96, p = 0.032). In the subgroup analysis of advanced RCC, obesity was associated with better prognosis than the normal group after applying multivariate analysis (p = 0.001).

CONCLUSIONS: Preoperative underweight could be a new independent factor to predict unfavorable cancer-specific survival in Korean patients with RCC treated by surgery. Moreover, obesity was verified to be associated with superior cancer-specific survival.

Written by:
Sung HH, Jeon SS, Park SY, Jeong BC, Seo SI, Lee HM, Choi HY. Are you the author?
Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Irwon-dong, Gangnam-gu, Seoul, Korea.

Reference: Cancer Causes Control. 2012 Mar;23(3):505-11.
doi: 10.1007/s10552-012-9910-4

PubMed Abstract
PMID: 22350955

UroToday.com Renal Cancer Section